Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants

NCT01815736 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1443

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV
HIV Infections

Interventions

DRUG: E/C/F/TAF
DRUG: E/C/F/TDF
DRUG: EFV/FTC/TDF
DRUG: RTV
DRUG: ATV
DRUG: FTC/TDF
DRUG: COBI

Sponsor

Gilead Sciences